Literature DB >> 26564433

Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

A Traboulsee1, J H Simon2, L Stone3, E Fisher4, D E Jones5, A Malhotra6, S D Newsome7, J Oh8, D S Reich9, N Richert10, K Rammohan11, O Khan12, E-W Radue13, C Ford14, J Halper15, D Li16.   

Abstract

An international group of neurologists and radiologists developed revised guidelines for standardized brain and spinal cord MR imaging for the diagnosis and follow-up of MS. A brain MR imaging with gadolinium is recommended for the diagnosis of MS. A spinal cord MR imaging is recommended if the brain MR imaging is nondiagnostic or if the presenting symptoms are at the level of the spinal cord. A follow-up brain MR imaging with gadolinium is recommended to demonstrate dissemination in time and ongoing clinically silent disease activity while on treatment, to evaluate unexpected clinical worsening, to re-assess the original diagnosis, and as a new baseline before starting or modifying therapy. A routine brain MR imaging should be considered every 6 months to 2 years for all patients with relapsing MS. The brain MR imaging protocol includes 3D T1-weighted, 3D T2-FLAIR, 3D T2-weighted, post-single-dose gadolinium-enhanced T1-weighted sequences, and a DWI sequence. The progressive multifocal leukoencephalopathy surveillance protocol includes FLAIR and DWI sequences only. The spinal cord MR imaging protocol includes sagittal T1-weighted and proton attenuation, STIR or phase-sensitive inversion recovery, axial T2- or T2*-weighted imaging through suspicious lesions, and, in some cases, postcontrast gadolinium-enhanced T1-weighted imaging. The clinical question being addressed should be provided in the requisition for the MR imaging. The radiology report should be descriptive, with results referenced to previous studies. MR imaging studies should be permanently retained and available. The current revision incorporates new clinical information and imaging techniques that have become more available.
© 2016 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26564433      PMCID: PMC5094650          DOI: 10.3174/ajnr.A4539

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  46 in total

1.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; B A C Cree; E C Crabtree; D S Goodin; E Waubant; D Pelletier
Journal:  Neurology       Date:  2011-01-26       Impact factor: 9.910

2.  Diagnostic value of 3D fluid attenuated inversion recovery sequence in multiple sclerosis.

Authors:  Carolin Gramsch; Felix Nensa; Oliver Kastrup; Stefan Maderwald; Cornelius Deuschl; Adrian Ringelstein; Juliane Schelhorn; Michael Forsting; Marc Schlamann
Journal:  Acta Radiol       Date:  2014-05-27       Impact factor: 1.990

3.  Scoring treatment response in patients with relapsing multiple sclerosis.

Authors:  M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano
Journal:  Mult Scler       Date:  2012-09-25       Impact factor: 6.312

4.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

5.  Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Authors:  Robert A Bermel; Xiaojun You; Pamela Foulds; Robert Hyde; Jack H Simon; Elizabeth Fisher; Richard A Rudick
Journal:  Ann Neurol       Date:  2013-01       Impact factor: 10.422

Review 6.  Treatment optimization in MS: Canadian MS Working Group updated recommendations.

Authors:  Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre
Journal:  Can J Neurol Sci       Date:  2013-05       Impact factor: 2.104

Review 7.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

8.  Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.

Authors:  J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

View more
  83 in total

Review 1.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

2.  Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis.

Authors:  J-M Tillema; S D Weigand; M Dayan; Y Shu; O H Kantarci; C F Lucchinetti; J D Port
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-26       Impact factor: 3.825

3.  Improved Detection of New MS Lesions during Follow-Up Using an Automated MR Coregistration-Fusion Method.

Authors:  A Galletto Pregliasco; A Collin; A Guéguen; M A Metten; J Aboab; R Deschamps; O Gout; L Duron; J C Sadik; J Savatovsky; A Lecler
Journal:  AJNR Am J Neuroradiol       Date:  2018-06-07       Impact factor: 3.825

4.  Improving Detection of Multiple Sclerosis Lesions in the Posterior Fossa Using an Optimized 3D-FLAIR Sequence at 3T.

Authors:  A Lecler; I El Sanharawi; J El Methni; O Gout; P Koskas; J Savatovsky
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

5.  Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Authors:  Derek J Erstad; Ian A Ramsay; Veronica Clavijo Jordan; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2019-11       Impact factor: 6.016

6.  A new frontier for amyloid PET imaging: multiple sclerosis.

Authors:  Silvia Morbelli; Matteo Bauckneht; Selene Capitanio; Matteo Pardini; Luca Roccatagliata; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-15       Impact factor: 9.236

7.  FLAIRfusion Processing with Contrast Inversion : Improving Detection and Reading Time of New Cerebral MS Lesions.

Authors:  M A Schmidt; R A Linker; S Lang; H Lücking; T Engelhorn; S Kloska; M Uder; A Cavallaro; A Dörfler; P Dankerl
Journal:  Clin Neuroradiol       Date:  2017-03-06       Impact factor: 3.649

Review 8.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

9.  Increased Curvature of the Tentorium Cerebelli in Idiopathic Intracranial Hypertension.

Authors:  P P Morris; N Lachman; D F Black; R A Carter; J Port; N Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

10.  Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.

Authors:  Augustin Lecler; C Bouzad; R Deschamps; F Maizeroi; J C Sadik; A Gueguen; O Gout; H Picard; J Savatovsky
Journal:  J Neurol       Date:  2019-08-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.